3.1 Verapamil

3.1.1 Status and why it is first-line

Verapamil is a non-dihydropyridine L-type calcium channel blocker, licensed for hypertension, angina and arrhythmia — not for cluster headache in most jurisdictions. It is nonetheless described as “the medication of choice” for CH prevention and “the most effective treatment with the best scientific evidence, followed by lithium” (PMC8748342). peer-reviewed

Its efficacy in CH was first described by Meyer and Hardenberg in 1983 (Schmerzklinik Kiel, German-language). peer-reviewed (German-language source.)

In 2025 the WHO Expert Committee on Selection and Use of Essential Medicines reviewed verapamil for CH prophylaxis and the reviewer “supports inclusion of verapamil for the prevention of cluster headache attacks, although the evidence supporting efficacy is limited” — the evidence base being two small RCTs and three observational studies (WHO 25th EML Expert Committee review). preprint / trial (WHO expert review document, not peer-reviewed journal publication.) Proposed EML formulations: immediate-release 40/80/120 mg, extended-release 120/180/240 mg.

Note the honest framing: the world’s most-prescribed CH preventive rests on two small trials.

3.1.2 Efficacy — the actual numbers

The pivotal placebo-controlled trial

Leone M, D’Amico D, Frediani F, et al. Verapamil in the prophylaxis of episodic cluster headache: a double-blind study versus placebo. Neurology 2000;54(6):1382–1385, DOI 10.1212/WNL.54.6.1382. peer-reviewed

Endpoint	Verapamil 360 mg/day	Placebo
n	30 total, randomised	—
Daily attack frequency	0.66 ± 0.88	1.65 ± 1.01
Daily analgesic consumption	0.5 ± 0.87	1.2 ± 1.03
≥50% reduction (week 2)	80%	0%
Attack-free	27%	—
p	<0.001 for attack frequency	—

Confirmed independently in the WHO review’s reproduction of the same trial (WHO 2025). preprint / trial

Read that table carefully. An 80% responder rate sounds superb. But “responder” here means ≥50% reduction in attack frequency over two weeks in episodic CH — and only 27% became attack-free. Roughly three-quarters of even the responders were still having attacks. For a chronic daily patient, the 27% figure is the more honest anchor.

Verapamil vs lithium head-to-head

Bussone G, Leone M, Peccarisi C, et al. Double blind comparison of lithium and verapamil in cluster headache prophylaxis. Headache 1990;30(7):411–417, DOI 10.1111/j.1526-4610.1990.hed3007411.x. peer-reviewed 23-week double-blind crossover, n=30 chronic CH, no placebo arm. Verapamil 360 mg/day vs lithium 900 mg/day. Headache Index reduction 50% (verapamil) vs 37% (lithium); Analgesic Consumption reduction 58% in both. Minor side effects 12% verapamil vs 29% lithium (Spanish-hosted review of lithium literature, SciELO). peer-reviewed (Article in English, hosted on the Spanish SciELO platform, European Journal of Psychiatry 2009;23(1), Zaragoza.)

Notice this trial had no placebo arm, so it establishes non-inferiority of two drugs to each other, not efficacy.

Open-label data — the optimistic end

• Blau JN & Engel HO open trial, n=72 (52 episodic, 18 chronic), starting 200 mg, most needing 200–480 mg, 12 patients needing 520–960 mg: complete relief in 49/52 episodic (94%) and 10/18 chronic (55%) (PMC8748342). peer-reviewed
• Open study, n=84: 33/84 (69%) improved by >75% in attack frequency (PMC8748342); the same 69%/>75% figure is cited by Schmerzklinik Kiel (German). peer-reviewed
• Pair-wise meta-analysis of open-label studies: 87% reached complete response or >50% reduction (PMC8748342). peer-reviewed

Open-label data — the pessimistic end, and a genuine conflict

The WHO 2025 review reports two different pooled figures within the same document: the detailed section gives a pooled observational figure of 73% (95% CI 0.59–0.84) reaching complete response or ≥50% reduction, while the reviewer summary states 87% (WHO 2025). preprint / trial This is an internal inconsistency in a WHO document, flagged here rather than resolved. Which figure the committee acted on is unknown.

More importantly, real-world clinic data are dramatically worse than trial data. The Danish Cluster Headache Survey (n=400, tertiary headache centre, Rigshospitalet/Danish Headache Center) found only 44% of episodic and 34% of chronic patients achieved >50% reduction on verapamil, and only 14% achieved complete relief. A separate Danish cohort found a 20% response rate. [CITIZEN-SCIENCE / PEER-REVIEWED hybrid] — this is a structured clinic-based patient survey published in the peer-reviewed literature; Petersen et al.’s Danish survey is one of the nine surveys catalogued in Rusanen SS, De S, Schindler EAD, Artto VA, Storvik M. Curr Pain Headache Rep 2022;26(8):623–637, PMC9436841.

The conflict is real and should not be smoothed over: open-label specialist trials report 69–94% response; a large Scandinavian real-world survey reports 34–44%. Likely contributors: responder-favourable publication in open series, differing definitions of “response”, tertiary centres accumulating treatment-refractory patients, and the fact that early open trials predate modern ICHD diagnostic rigour. Which is closer to your likely experience is genuinely uncertain — but if you are chronic and attending a specialist centre, the Danish numbers are the better prior.

Time to effect

• EAN guideline: effect takes 14–21 days (European Academy of Neurology guidelines on cluster headache, 2023, DOI 10.1111/ene.15956). peer-reviewed
• German G-BA/Schmerzklinik Kiel: efficacy assessable “at the earliest after 1 week”, onset dose-dependent (German). peer-reviewed
• Gabai & Spierings: onset 1.7 weeks episodic, 5 weeks chronic — chronic patients wait roughly three times as long. peer-reviewed

This chronic/episodic latency difference matters practically: a chronic patient who abandons a dose after two weeks may be abandoning a dose that would have worked at week five.

3.1.3 Dosing and titration — four national protocols compared

There is no international consensus. Here are four, side by side.

Source	Start	Increment	Max	Notes
EAN 2023 (ene.15956)	80 mg TID or QID	+80 mg every 3–4 days	~1000 mg/day	Taper over 2–4 weeks on stopping
BASH (UK) (BASH verapamil regime)	320 mg/day (80/80/160)	Fixed 9-stage ladder, each stage held 2 weeks, ECG before each step	960 mg/day	Explicitly “does not have a specific licence for a headache condition”
Australian Prescriber 2022 (Ray JC, Stark RJ, Hutton EJ. Aust Prescr 2022;45:15–20, DOI 10.18773/austprescr.2022.004)	80 mg TID for ≥2 weeks	+80 mg every 2 weeks	240–960 mg/day	Grade 1B
German G-BA (statutory) (Schmerzklinik Kiel, German)	120 mg/day	Not specified	360 mg/day	Above 360 mg = back into off-label
Schmerzklinik Kiel clinical practice (same page)	2 × 120 mg SR, 12 h apart; or 2 × 240 mg if severe	+step every 3–7 days	240–960 mg, up to 1200 mg inpatient	Directly contradicts the G-BA limit

peer-reviewed for EAN and Australian Prescriber; preprint / trial for BASH (clinical guidance document, not a peer-reviewed article) and the G-BA regulatory decision.

The full BASH 9-stage ladder (BASH): 80/80/160 (320) → 80/160/160 (400) → 160/160/160 (480) → 160/160/240 (560) → 160/240/240 (640) → 240/240/240 (720) → 240/240/320 (800) → 240/320/320 (880) → 320/320/320 (960). Each stage is held two weeks and requires a normal ECG before advancing. At that pace, reaching 960 mg takes ~18 weeks. preprint / trial

A Delphi consensus of headache specialists found the mean highest verapamil dose used was 550 mg/day (range 240–960) (Koppen H, et al. Cephalalgia 2016, DOI 10.1177/0333102416631968). peer-reviewed So real specialist practice sits around 550 mg — well above the German statutory 360 mg cap and well below the 960 mg ceiling.

Immediate-release vs sustained-release: an unresolved and clinically important disagreement

• Schmerzklinik Kiel (Germany) states only sustained-release (“retardierte”) 12-hour preparations should be used, because IR verapamil “produces fluctuations and gaps in plasma levels, reduces effectiveness, and allows the level to fall at night” — which matters given the nocturnal attack peak (German). peer-reviewed
• The G-BA decision itself does not state whether IR or SR should be used (same source). preprint / trial
• The patient community holds the exact opposite view — see §1.5.

This is a genuine, unresolved conflict with no adequate head-to-head data. Unknown.

3.1.4 ECG monitoring: rationale and protocol

Why

Verapamil slows AV nodal conduction. In CH it is used at 2–4× cardiac doses, for years, in an otherwise healthy population. The observed harms are not theoretical.

Cohen AS, Matharu MS, Goadsby PJ — n=217, mean dose 512 mg/day: 19% developed arrhythmias, PR prolongation the most common finding. 41% had never had an ECG at all. peer-reviewed

Lanteri-Minet M, et al. (French group), cardiac safety of very-high-dose verapamil (PMC3072493): of 200 CH patients, 29 (14.8%) received high doses of 877 ± 227 mg/day. Among those 29: ECG changes in 38% (11/29); bradycardia in 7 (24%) classed non-serious; arrhythmia (heart block) in 4 (14%) classed a serious adverse event. Mean dose in those with ECG changes 1003 ± 295 mg/day vs 800 ± 143 mg/day in those without. peer-reviewed

Two findings from that study deserve emphasis because they break the intuitive mental model:

1. Roughly three-quarters of cardiac adverse effects had markedly delayed onset — appearing after more than 2 years of treatment (PMC3072493, summarised in German at Schmerzklinik Kiel). A clean ECG at month 3 does not buy you safety at year 3.
2. Adverse events were reported as independent of dose level (same source). BASH puts it even more bluntly: rhythm disturbances are “neither dose-dependent nor time-dependent” (BASH). preprint / trial This is why “I’m only on 240 mg so I don’t need ECGs” is not a defensible position.

Australian Prescriber states plainly: “one in five patients will develop an arrhythmia” (Aust Prescr 2022;45:15–20). peer-reviewed

Protocols

Source	Baseline	On titration	At stable dose
EAN 2023	Mandatory before treatment	Repeat with each +160 mg above 480 mg/day	—
BASH (UK)	Yes	Before every dose step (must be normal to advance)	Every 6 months
Australian Prescriber 2022	Yes	Every dose change	At stable dose after 10 days, then every 1–2 months, then every 6 months
Schmerzklinik Kiel (Germany)	Mandatory, assess PQ interval	1–2 weeks after every dose increase	Every 6 months if AV block unchanged; stop if worsening
Koppen Delphi (specialist actual practice)	82% do one	50% before increase; 60% after (mean 5 days, range 1–14)	Holter at ≥480 mg/day in 50%

Sources: EAN 2023, BASH, Aust Prescr 2022, Schmerzklinik Kiel, German, Koppen 2016 Delphi, DOI 10.1177/0333102416631968. peer-reviewed except BASH preprint / trial.

The German source gives the most operationally precise thresholds available anywhere — worth quoting because most English-language guidance gives none (Schmerzklinik Kiel, German): peer-reviewed

• PQ > 0.20 s = first-degree AV block → an application restriction, not an absolute contraindication; if there is a strict indication, first follow-up ECG at 1–2 weeks
• PQ ≈ 0.25 s → generally should not prescribe
• PQ ≥ 0.30 s → should in any case not prescribe
• Second-degree AV block or higher → absolute contraindication
• Suspected heart failure → contraindication
• Beta-blockers must not be co-administered
• Recommend interdisciplinary follow-up with a cardiologist
• No deaths during verapamil CH prophylaxis had been reported in the cited material; no embryotoxicity known

Full BASH contraindication list: acute porphyrias; atrial flutter/fibrillation with accessory pathway (e.g. WPW); bradycardia; cardiogenic shock; history of heart failure even if controlled; history of significantly impaired LV function even if controlled; hypotension; 2nd/3rd-degree AV block; sick sinus syndrome; sino-atrial block. Not recommended in pregnancy, planned pregnancy or breastfeeding (BASH). preprint / trial

Also: slow tapering is strictly recommended on discontinuation to avoid cardiac complications (WHO 2025; PMC8748342). EAN says taper over 2–4 weeks.

3.1.5 Side effects

Guideline/trial-derived: hypotension, fatigue, constipation, oedema, bradycardia, AV block (PMC8748342). peer-reviewed Constipation and oedema can be dose-limiting; rare severe skin reactions (WHO 2025). preprint / trial

BASH’s fuller patient-facing list adds: abnormal heartbeat, flushing, nausea, abdominal pain, dizziness, vertigo, tinnitus, tiredness, tremor, movement disorders, muscle weakness, joint/muscle aches, rash or itching, paraesthesia, swollen gums, numbness, hair loss, rare impotence, and rare galactorrhoea in males and females (reversible on cessation) (BASH). preprint / trial Swollen gums (gingival hyperplasia) and hair loss are under-communicated in clinical practice and worth knowing about in advance.

Comparative tolerability: minor side effects 12% verapamil vs 29% lithium in Bussone’s head-to-head (SciELO review); Australian Prescriber similarly reports 29% lithium vs 12% verapamil (Aust Prescr 2022). peer-reviewed

3.1.6 What the patient community says — verapamil

Drawn from three r/clusterheads threads (~40 identifiable participants total). community report throughout this subsection.

Doses actually used are frequently at or above the ceiling of most guidelines. Reported personal doses include 480 mg (thread), 600 mg (self-escalated without telling the doctor), 680 mg, 720 mg, 960 mg, and one patient on 3 × 340 mg = 1020 mg/day for seven years (thread).

Time to effect, reported: “within a week” at 480 mg; ~1 week; “about two weeks to assess whether a dose is working”; one patient took a full year to titrate to 680 mg with an ECG between each step (thread).

Effectiveness is bimodal, not graded. Reports cluster into “largely stopped my attacks” and “did nothing”:

“After starting verapamil at a dosage of 480mg, I noticed a significant improvement—within a week, I was free from cluster headaches!” (r/clusterheads)

“I’ve been taking it for about three years now and it has worked very well. Have gone from ~40 headaches a year to maybe 5 and haven’t had side effects.” (r/clusterheads)

“It doesn’t work for me.” (r/clusterheads)

Side effects, community-weighted differently from the literature. Constipation dominates:

“In a single word, my experience with Verapamil can be summed up as ‘constipation.’” (r/clusterheads)

Also reported: bradycardia (“my heart rate is VERY slow. Resting Heart rate of an Olympic athlete” at 960 mg/day); fatigue and loss of motivation; ankle swelling; palpitations and light-headedness severe enough to stop the drug within a month; cold hands and feet; weight gain; hormonal imbalance; reduced sexual function; inability to raise heart rate during exercise, making exercise “impossible”; and one report of developing an allergy after several years (threads 1, 2, 3).

Four places where community experience diverges sharply from trial/guideline data

(a) ECG monitoring is frequently not happening. Guidelines are near-unanimous that ECGs are mandatory. Patients report otherwise:

“I never had (or was told to have) ECGs, even though I mentioned heart symptoms during my annual check-up.” (r/clusterheads)

Another reported severe palpitations and light-headedness and said the doctor “never tested them or checked the symptoms.” Meanwhile Cohen’s peer-reviewed series found 41% of 217 patients had never had an ECG despite a mean dose of 512 mg/day — so the community observation and the published data agree exactly. This convergence is the strongest signal in the chapter: monitoring failure is documented in both anecdote and peer-reviewed cohort data.

(b) Immediate-release vs sustained-release — the community says the opposite of the German clinic. German specialists insist on SR for stable nocturnal levels. Multiple community members report the reverse:

“Sustained-release verapamil is considered less effective for cluster prevention… dosing every 6–8 hours maintains a higher, more consistent blood concentration.” — paraphrased community claim, presented as testimonials, not trial results (r/clusterheads)

Another simply: “the SR version did not work” (r/clusterheads). This is an unresolved empirical question with no adequate trial. Neither side has good data. Contested.

(c) Patients routinely self-escalate past doctor-imposed caps, and sometimes report benefit from doing so. One patient held at 440 mg because of an APC/ECG finding self-adjusted the regimen and reported “The result? My headaches disappeared” — the doctor was initially upset, then approved a modified regimen and documented the self-alteration in the notes (r/clusterheads). Another was capped at 480 mg despite reporting greater benefit at 600 mg. One explanation offered by a patient: their neurologist “was kind but inexperienced with chronic cluster headache and the patient was the neurologist’s first chronic case.” This is risky behaviour given the documented 14% serious-arrhythmia rate at high doses — but it is happening, and the German literature suggests the low caps may genuinely be wrong (see below).

(d) One reported pattern with no trial correlate: episodic → chronic conversion on verapamil. A patient reported that after several treatment cycles it became impossible to stop verapamil without CH returning, that an initially episodic condition became chronic while taking it, and that after tapering off over nearly a year they became episodic again (r/clusterheads). community report — This is a single anecdote, entirely unverified, with an obvious confound (chronification is the natural history in a subset of episodic patients regardless of treatment). It is recorded here because it is the sort of minority observation that would never surface in a 2-week RCT, not because it is credible evidence. Unknown.

The German off-label paradox — worth understanding in detail

In Germany the G-BA (Federal Joint Committee) formally added verapamil to the Arzneimittel-Richtlinie for prophylaxis of episodic and chronic CH in adults ≥18, making it prescribable on statutory health insurance beyond its licensed indication — a real access win. But it fixed the dose at initially 120 mg/day, maximum 360 mg/day, set the treatment goal at ≥50% attack reduction, said treatment should stop if that goal is not met, and stated episodic treatment generally lasts ~6 weeks (Schmerzklinik Kiel, German). preprint / trial (regulatory decision)

Reimbursement is further restricted to products from 1A/Hexal/Sandoz, Abbott, Aliud/Stada, Basics, Heumann and Wörwag only — other manufacturers’ verapamil may not be prescribed on a statutory prescription, because those companies did not submit statements and thus showed no interest in reimbursement eligibility (same source).

Hartmut Göbel’s clinic then criticises the decision head-on, in terms rarely seen in official commentary: 120 mg/day is too low for many patients; effective treatment may require 2 × 240 mg or more; many severely affected patients respond only above 360 mg; the 360 mg cap therefore returns those patients to off-label status; up to 480 mg is already approved for hypertension; the standardisation is “incompatible with the scientific literature”; specialist centres can disregard the limit but are then off-label “quantitatively and qualitatively”; routine-care physicians are unlikely to attempt high-dose treatment; and prescribers face legal exposure if they prescribe against the authorisation (Schmerzklinik Kiel, German). peer-reviewed (clinical commentary citing Göbel H, Die Kopfschmerzen, 3rd ed., Springer 2012)

Göbel also argues the treatment goal itself is wrong — that given the severity of cluster attacks, the goal should be complete freedom from attacks, not a 50% reduction. This is a substantive philosophical objection to how CH trials and reimbursement are framed, and it maps directly onto why the “80% responder rate” in Leone 2000 feels so much better on paper than in life.

3.1.7 2024–2026 updates

• WHO 2025 EML review recommended inclusion of verapamil (with prednisolone and subcutaneous sumatriptan) for CH, explicitly acknowledging limited evidence (WHO). preprint / trial If adopted, this is meaningful for global access, particularly in low- and middle-income countries.
• A 2025 Czech-language review (Neurologie pro praxi 2025;26(1):54–60) restates verapamil as first-line while explicitly acknowledging off-label status, recommending initiation as early as possible in the bout at 240 mg/day, conditional on excluding contraindications and a normal ECG. peer-reviewed (Czech-language source — note the higher starting dose than the German G-BA’s 120 mg.)
• Petersen AS et al. (2019, 2023) reviews from the Danish Headache Center continue to emphasise the limitations of the verapamil evidence base (PMC10476341). peer-reviewed
• No new verapamil RCT has been published in 2024–2026. The evidence base is still Leone 2000 and Bussone 1990. That is a 26-year gap in randomised evidence for the world’s first-line CH preventive. Worth sitting with.

3.1.8 Australia specifically

Verapamil is available in Australia and cheap, but off-label for CH — there is no PBS indication for cluster headache. Australian Prescriber gives it Grade 1B and the titration/ECG schedule in §1.3–1.4 (Ray JC, Stark RJ, Hutton EJ. Aust Prescr 2022;45:15–20). peer-reviewed Practical implication: your GP or neurologist can prescribe it, the cost is trivial, but the ECG monitoring burden falls on you to insist upon.